BRPI0512254A - peptìdeos ligantes ao fgfr - Google Patents
peptìdeos ligantes ao fgfrInfo
- Publication number
- BRPI0512254A BRPI0512254A BRPI0512254-6A BRPI0512254A BRPI0512254A BR PI0512254 A BRPI0512254 A BR PI0512254A BR PI0512254 A BRPI0512254 A BR PI0512254A BR PI0512254 A BRPI0512254 A BR PI0512254A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- fgfr
- ncam
- peptide sequences
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 abstract 4
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 108091008794 FGF receptors Proteins 0.000 abstract 3
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 abstract 3
- 102000002090 Fibronectin type III Human genes 0.000 abstract 1
- 108050009401 Fibronectin type III Proteins 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003061 neural cell Anatomy 0.000 abstract 1
- 230000014511 neuron projection development Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
PEPTìDEOS LIGANTES AO FGFR. A presente invenção está relacionada a compostos peptídeo capazes de se ligar diretamente ao receptor do fator de crescimento do fibroblasto (FGFR) e ativar o referido receptor. Os compostos da invenção compreendem fragmentos peptídeo da molécula de adesão de célula neural (NCAM) derivada do módulo fibronectina tipo-III (F3-1) da NCAM. As seqüências peptídeo da ubvebção são capazes de estimular o aprendizado e a memória e/ou crescimento neurítico resultante e/ou crescimento neurítico resultante e/ou sob revivência da célula neural. As seqüências peptídeos e os compostos que as compreendem, de acordo com a invenção, podem ser beneficamente utilizados para o tratamento e/ou prevenção de diferentes condições patológicas onde FGFR e/ou NCAM desempenham um papel na patologia e/ou recuperação da doença. Conseqüentemente, composições farmacêuticas compreendendo as seqüências e compostos peptídeo da invenção estão também no escopo de proteção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400963 | 2004-06-18 | ||
| PCT/DK2005/000400 WO2005123759A2 (en) | 2004-06-18 | 2005-06-17 | Fgfr binding peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512254A true BRPI0512254A (pt) | 2008-02-19 |
Family
ID=35510321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512254-6A BRPI0512254A (pt) | 2004-06-18 | 2005-06-17 | peptìdeos ligantes ao fgfr |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090074774A1 (pt) |
| EP (1) | EP1765861B1 (pt) |
| JP (1) | JP2008504236A (pt) |
| CN (1) | CN101027320A (pt) |
| AT (1) | ATE545655T1 (pt) |
| AU (1) | AU2005254613A1 (pt) |
| BR (1) | BRPI0512254A (pt) |
| CA (1) | CA2570267A1 (pt) |
| MX (1) | MXPA06014804A (pt) |
| WO (1) | WO2005123759A2 (pt) |
| ZA (1) | ZA200610546B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7847058B2 (en) * | 2003-09-30 | 2010-12-07 | Elisabeth Bock | Method of modulating cell survival, differentiation and/or synaptic plasticity |
| EP2412726B1 (en) | 2006-02-14 | 2016-06-15 | University Of Tasmania Through The Menzies Research Institute | Metallothionein-derived peptide fragments |
| WO2007110079A2 (en) * | 2006-03-29 | 2007-10-04 | Enkam Pharmaceuticals A/S | Targeted delivery of fgfr ligands into the brain |
| CN101619093B (zh) * | 2009-05-26 | 2011-12-07 | 中国人民解放军第三军医大学野战外科研究所 | 具有促进成纤维细胞生长因子受体3活性的多肽及其筛选方法和应用 |
| CN102869775A (zh) | 2009-09-30 | 2013-01-09 | 哈佛大学校长及研究员协会 | 通过调节自噬抑制基因产物调节自噬的方法 |
| EP2854836B1 (en) | 2012-06-05 | 2018-04-04 | The Board of Trustees of The Leland Stanford Junior University | Ncam peptide mimetic for use in treating major depression disorder |
| CN109867724B (zh) * | 2019-04-19 | 2020-09-15 | 温州医科大学 | 一种fgfr抗体及其在脊髓损伤治疗中的用途 |
| EP4682157A1 (en) * | 2023-03-17 | 2026-01-21 | FUJIFILM Corporation | Cyclic peptide or salt thereof, and use for same |
| CN116199744B (zh) * | 2023-03-23 | 2024-06-25 | 湖南中晟全肽生物科技股份有限公司 | 一种结合fgfr2受体的多肽及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020104122A1 (en) * | 1994-06-17 | 2002-08-01 | Kirin Beer Kabushiki Kaisha | Methods for producing a plant with enhanced resistance to pathogenic fungi |
| GB0014870D0 (en) * | 2000-06-16 | 2000-08-09 | King S College London | Peptides |
| EP1434798B1 (en) * | 2001-08-17 | 2012-04-04 | Enkam Pharmaceuticals A/S | Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells |
| CA2546873A1 (en) * | 2003-11-21 | 2005-06-02 | Ace Biosciences A/S | Surface-located campylobacter jejuni polypeptides |
-
2005
- 2005-06-17 CN CNA2005800284125A patent/CN101027320A/zh active Pending
- 2005-06-17 AT AT05748535T patent/ATE545655T1/de active
- 2005-06-17 BR BRPI0512254-6A patent/BRPI0512254A/pt not_active Application Discontinuation
- 2005-06-17 WO PCT/DK2005/000400 patent/WO2005123759A2/en not_active Ceased
- 2005-06-17 CA CA002570267A patent/CA2570267A1/en not_active Abandoned
- 2005-06-17 MX MXPA06014804A patent/MXPA06014804A/es not_active Application Discontinuation
- 2005-06-17 AU AU2005254613A patent/AU2005254613A1/en not_active Abandoned
- 2005-06-17 EP EP05748535A patent/EP1765861B1/en not_active Expired - Lifetime
- 2005-06-17 JP JP2007515781A patent/JP2008504236A/ja active Pending
- 2005-06-17 US US11/629,896 patent/US20090074774A1/en not_active Abandoned
-
2006
- 2006-12-15 ZA ZA200610546A patent/ZA200610546B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005123759A2 (en) | 2005-12-29 |
| JP2008504236A (ja) | 2008-02-14 |
| ATE545655T1 (de) | 2012-03-15 |
| EP1765861A2 (en) | 2007-03-28 |
| WO2005123759A3 (en) | 2006-05-04 |
| US20090074774A1 (en) | 2009-03-19 |
| AU2005254613A1 (en) | 2005-12-29 |
| CA2570267A1 (en) | 2005-12-29 |
| MXPA06014804A (es) | 2007-03-23 |
| WO2005123759A8 (en) | 2006-03-09 |
| EP1765861B1 (en) | 2012-02-15 |
| CN101027320A (zh) | 2007-08-29 |
| ZA200610546B (en) | 2008-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0512254A (pt) | peptìdeos ligantes ao fgfr | |
| WO2004078777A3 (en) | Dipeptidyl-peptidase protected proteins | |
| WO2007093177A3 (en) | Metallothionein-derived peptide fragments | |
| WO2009004315A8 (en) | Isolated peptides and uses thereof | |
| BRPI0413373A (pt) | compostos compreendendo lpa | |
| NO992463D0 (no) | N-(aryl/heteroarylacetyl)aminosyreestere, farmas°ytiske sammensetninger som omfatter det samme, og metoder for inhibering av <beta>-amyloidpeptidfrigivelse og/eller dens syntese ved bruk av slike forbindelser | |
| WO2008069876A3 (en) | Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation | |
| WO2007051477A8 (en) | Neurotrophin-derived peptide sequences | |
| WO2006119767A3 (en) | Neuritogenic peptides | |
| FR2866345B1 (fr) | Procede de traitement d'un gaz naturel avec extraction du solvant contenu dans le gaz naturel purifie | |
| DK1373502T3 (da) | Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf | |
| WO2007019860A3 (en) | Gdnf derived peptides | |
| Hanessian et al. | Structure-based organic synthesis of unnatural aeruginosin hybrids as potent inhibitors of thrombin | |
| Sato et al. | Degradation-promoters of cellular inhibitor of apoptosis protein 1 based on bestatin and actinonin | |
| WO2006110588A3 (en) | Methods for treating mild cognitive impairment | |
| WO2009068042A3 (en) | Novel peptides derived from ncam (fgls) | |
| WO2005025514A3 (en) | Compounds that modulate neuronal growth and their uses | |
| WO2007074456A3 (en) | Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids | |
| WO2003065997A3 (en) | Anti-infarction molecules | |
| WO2007071248A3 (en) | Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins | |
| WO2007045243A3 (en) | Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1 | |
| WO2007013358A3 (en) | Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent | |
| WO2003097687A3 (en) | Neuroprotective polypeptides and methods of use | |
| DK1438329T3 (da) | Biologisk aktive peptider og deres anvendelse til reparation af beskadigede nerver | |
| WO2005121168A3 (en) | Heparin binding peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |